Healthcare Services

A key trend shaping the HER2-Positive Breast Cancer Market involves the Innovative Therapies In The HER2-Positive Breast Cancer Market

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The HER2-Positive Breast Cancer Market Over The 2026–2030 Period?

The her2-positive breast cancer market has experienced robust expansion over the past few years. It is projected to advance from $10.93 billion in 2025 to $11.7 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.1%. This historical growth can be primarily attributed to an increasing identification of her2-positive cases, the expansion of targeted oncology drug approvals, the development of hospital oncology infrastructure, the availability of monoclonal antibody therapies, and rising clinical trial activity.

The her2-positive breast cancer market is projected to experience robust expansion over the coming years. This market is anticipated to reach $15.23 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. This growth during the projected period stems from several factors, including the rising adoption of next-generation her2 inhibitors, wider biosimilar penetration, an increasing need for precision oncology treatments, greater investment in targeted cancer research, and a sharpened focus on enhancing survival outcomes. Key trends anticipated for this forecast span the growing uptake of her2-targeted antibody therapies, an increasing application of antibody-drug conjugates, the broadening of companion diagnostic testing, an elevated emphasis on early-stage targeted treatment, and improved integration of combination therapy strategies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20832&type=smp

Which Economic Or Industry Drivers Are Impacting The HER2-Positive Breast Cancer Market?

The increasing acceptance and utilization of immunotherapy are projected to propel the expansion of the HER2-positive breast cancer market moving forward. Immunotherapy refers to a medical treatment designed to boost or alter the immune system’s natural capacity to combat diseases such as cancer, infections, and autoimmune conditions. Its widespread adoption is attributed to its ability to enhance the immune system’s power to identify and eliminate cancer cells, offering superior efficacy and fewer adverse effects compared to traditional therapies. Immunotherapy assists in HER2-positive breast cancer by strengthening the body’s immune system to recognize and attack HER2-overexpressing cancer cells, thereby improving treatment outcomes and reducing the risk of recurrence. For instance, in July 2023, the American Association for Cancer Research, a US-based organization, indicated that the FDA had approved 11 immune checkpoint inhibitors (ICIs) in 2023, with at least one ICI authorized for the treatment of 20 different cancer types and for any solid tumor exhibiting specific molecular characteristics. Thus, the significant adoption of immunotherapy is a key driver for the growth of the HER2-positive breast cancer market.

How Is The HER2-Positive Breast Cancer Market Segmented Across Key Categories?

The her2-positive breast cancer market covered in this report is segmented –

1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types

2) By Route Of Administration: Parenteral, Oral, Other Routes Of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User

Subsegments:

1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors

2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens

3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy

4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation

5) By Other Treatment Types: Radiation Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)

What Trends Are Projected To Affect The HER2-Positive Breast Cancer Market?

Leading companies in the HER2-positive breast cancer market are focused on developing innovative therapies, such as HER2-directed antibody-drug conjugates (ADCs), to optimize and enhance the patient treatment process. HER2-directed ADCs are targeted cancer therapies that combine an antibody specific to HER2 with a cytotoxic drug, ensuring direct delivery of the drug to HER2-positive cancer cells for more effective treatment. For example, in January 2024, AstraZeneca India Pharma Ltd., an India-based biopharmaceutical company, introduced Trastuzumab deruxtecan. This innovative therapy was developed through a collaboration between AstraZeneca and Daiichi Sankyo. Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate (ADC) that delivers a cytotoxic drug directly to HER2-positive cancer cells, providing a more targeted and effective treatment for patients.

Who Are The Dominant Players Shaping The HER2-Positive Breast Cancer Market Landscape?

Major companies operating in the her2-positive breast cancer market are F. Hoffmann-La Roche AG, AstraZeneca plc, Novartis International AG, Pfizer Inc., Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Seagen Inc., MacroGenics Inc., BioNTech SE, Incyte Corporation, Zymeworks Inc., Ambrx Biopharma Inc., Mersana Therapeutics Inc.

Read the full her2-positive breast cancer market report here:

https://www.thebusinessresearchcompany.com/report/her2-positive-breast-cancer-global-market-report

What Are The Top-Performing Regions Within The HER2-Positive Breast Cancer Market?

North America was the largest region in the HER2- positive breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the her2-positive breast cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored HER2-Positive Breast Cancer Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20832&type=smp

Browse Through More Reports Similar to the Global HER2-Positive Breast Cancer Market 2026, By The Business Research Company

Breast Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Breast Cancer Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Metastatic Hr Her2 Breast Cancer Global Market Report

https://www.thebusinessresearchcompany.com/report/metastatic-hr-her2-breast-cancer-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795